Modified bacteriophage
AssigneePhico Therapeutics Ltd.
InventorsHeather FAIRHEAD, Adam WILKINSON
Life of this patent
Estimating the term…
Abstract
A modified bacteriophage capable of infecting a plurality of different target bacteria, which bacteriophage includes a toxin gene encoding a toxin protein which is toxic to the target bacteria; wherein the bacteriophage is lytic; and wherein the bacteriophage expresses host range determinant proteins which have a plurality of bacterial host specificities.
Claims45
A modified bacteriophage capable of infecting a plurality of different target bacteria, which bacteriophage includes a toxin gene encoding a toxin protein which is toxic to the target bacteria;
- wherein the bacteriophage is lytic;
- and wherein the bacteriophage expresses host range determinant proteins which have a plurality of bacterial host specificities.
A modified bacteriophage according to any one of the preceding claims, wherein the toxin gene is under the control of a constitutive promoter.
A modified bacteriophage according to any one of the preceding claims, wherein at least one of the target bacteria is Pseudomonas.
A modified bacteriophage according to any one of the preceding claims, wherein the hybrid host range determinants have a broad host range as defined by more than 50% of a collection of at least 35 and preferably more than 50 clinical isolates, from a plurality of different infection sites and including a range of antibiotic resistance phenotypes.
A modified bacteriophage according to any one of the preceding claims, wherein the host range determinants comprise tail fibre proteins.
A modified bacteriophage according to any one of the preceding claims wherein the host range determinant proteins are hybrid host range determinant proteins each comprising an amino acid sequence from a plurality of different bacteriophages.
A modified bacteriophage according to any one of the preceding claims in admixture with at least one other modified bacteriophage which is capable of infecting target bacteria, which includes a SASP gene encoding a SASP which is toxic to the target bacteria.
A modified bacteriophage according to any one of the preceding claims, for use as a medicament.
A modified bacteriophage according to any one of the preceding claims, for use in the treatment of bacterial infection.
Dependencies are inferred from the claim text.